Clinical Trial

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a Phase II/III, randomized, multicenter, open-label clinical trial designed to evaluate safety and efficacy of RC48-ADC combine with Toripalimab and chemotherapy or RC48-ADC combine with Toripalimab and Trastuzumab as first-line treatment in human epidermal growth factor receptor 2 (HER2)-expression or non-expression participants with locally advanced or metastatic gastric cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-07; most recent amendment 2025-09-23.
Status change: Recruiting → Active, Not Recruiting 2025-09-23
Status change: Not Yet Recruiting → Recruiting 2023-11-23
Trial Details
NCT Number NCT05980481
Lead Sponsor RemeGen Co., Ltd.
Conditions Gastric Cancer
Enrollment 201 participants
Start Date 2023-08-04
Primary Completion 2025-07-10 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-29